Profile data is unavailable for this security.
About the company
Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and are reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are found in the bodily fluids of humans and food. The Company conducted all the Phase II clinical trials for the treatment of a variety of cancers using the combination of Antineoplastons A10 and AS2-1. Most of the trials involve the use of intravenous formulations of Antineoplastons; however, a few trials use oral formulations. The Company has not generated any operating revenue since its inception. The Company's clinical trials are conducted at the Burzynski Clinic.
- Revenue in USD (TTM)0.00
- Net income in USD-1.54m
- Incorporated1980
- Employees2.00
- LocationBurzynski Research Institute Inc12000 Richmond AveHOUSTON 77082United StatesUSA
- Phone+1 (713) 335-5697
- Fax+1 (713) 935-0649
- Websitehttp://burzynskiresearch.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exicure Inc | 500.00k | -8.17m | 4.76m | 5.00 | -- | 2.95 | -- | 9.52 | -4.72 | -4.72 | 0.2889 | 0.9323 | 0.0354 | -- | -- | 83,333.34 | -57.87 | -41.52 | -69.90 | -55.78 | -- | -- | -1,634.40 | -290.95 | -- | -- | 0.3827 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 4.80m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Portage Biotech Inc | 0.00 | -71.08m | 4.81m | 7.00 | -- | 1.92 | -- | -- | -68.81 | -68.81 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -137.29 | -30.53 | -143.21 | -40.02 | -- | -- | -- | -- | -- | -- | 0.02 | -- | -- | -- | 27.98 | -- | -- | -- |
| Raphael Pharmaceutical Inc | 0.00 | -1.40m | 4.86m | 0.00 | -- | -- | -- | -- | -0.0803 | -0.0803 | 0.00 | -0.0155 | 0.00 | -- | -- | -- | -1,134.41 | -- | -- | -- | -- | -- | -- | -- | -- | -139.10 | -- | -- | -- | -- | 61.76 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 17.00k | -5.73m | 4.91m | 4.00 | -- | 0.4939 | -- | 289.00 | -4.07 | -4.07 | 0.012 | 5.69 | 0.0015 | 1.00 | -- | 4,250.00 | -51.83 | -110.00 | -53.71 | -- | 60.00 | 65.82 | -33,716.41 | -7,961.14 | 20.20 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
| Polyrizon Ltd | 0.00 | -997.00k | 5.05m | 1.00 | -- | -- | -- | -- | -0.2377 | -0.2377 | 0.00 | 0.0529 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.93 | 0.4048 | -- | -- | -- | 22.98 | -- | -- | -- |
| Windtree Therapeutics Inc | 0.00 | -11.38m | 5.12m | 15.00 | -- | 0.0991 | -- | -- | -0.7463 | -0.7463 | 0.00 | 17.65 | 0.00 | -- | -- | 0.00 | -32.86 | -44.51 | -40.15 | -48.38 | -- | -- | -- | -94,533.34 | -- | -- | 0.1612 | -- | -- | -- | 48.25 | -- | -- | -- |
| Burzynski Research Institute Inc | 0.00 | -1.54m | 5.39m | 2.00 | -- | -- | -- | -- | -0.0117 | -0.0117 | 0.00 | -0.0007 | 0.00 | -- | -- | -- | -89,888.89 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
| Dogwood Therapeutics Inc | 0.00 | -5.30m | 5.73m | 4.00 | -- | 1.52 | -- | -- | -6.51 | -6.51 | 0.00 | 2.82 | 0.00 | -- | -- | 0.00 | -119.71 | -79.80 | -135.31 | -89.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 56.76 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -15.97m | 5.79m | 3.00 | -- | -- | -- | -- | -134.04 | -134.04 | 0.00 | -2.97 | 0.00 | -- | -- | 0.00 | -358.12 | -132.47 | -- | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
| Xenetic Biosciences Inc | 2.52m | -4.70m | 5.80m | 4.00 | -- | 0.7784 | -- | 2.30 | -3.05 | -3.05 | 1.64 | 4.83 | 0.2314 | -- | -- | 630,087.50 | -43.12 | -48.91 | -48.61 | -52.82 | -- | -- | -186.33 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
| TFF Pharmaceuticals Inc | 1.20m | -19.39m | 5.82m | 19.00 | -- | 0.9277 | -- | 4.84 | -7.95 | -7.95 | 0.4659 | 1.81 | 0.1043 | -- | 3.51 | 63,293.68 | -168.10 | -79.57 | -212.66 | -83.41 | -- | -- | -1,612.04 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
| Check Cap Ltd | 0.00 | -17.57m | 5.85m | 85.00 | -- | 0.247 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
| Eterna Therapeutics Inc | 162.00k | -23.94m | 5.94m | 8.00 | -- | -- | -- | 36.69 | -4.42 | -4.42 | 0.0299 | -1.58 | 0.0035 | -- | 0.2673 | 20,250.00 | -51.20 | -169.05 | -62.39 | -223.00 | -111.11 | -- | -14,765.43 | -682.61 | -- | -10.12 | 10.22 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
